Skip to main content

Symptoms in Advanced Hematologic Malignancies and Other Serious Hematologic Conditions

  • Chapter
  • First Online:
Palliative Care in Hematologic Malignancies and Serious Blood Disorders

Abstract

This chapter will cover both common and uncommon non-pain symptoms associated with malignancies. Cancer-related fatigue (CRF) is described as a subjective sensation of tiredness out of proportion to any change in activity and severe enough to affect function. Cancer related may be a disorder of a sense of effort and central in origin. Exercise, corticosteroids, American ginseng, and psychostimulants may improve fatigue. Cachexia complex metabolic syndrome is characterized primarily by weight loss (5% weight loss over 6 months) which is most often accompanied by of muscle, adipose tissue, anorexia, anemia, and reduced physical function. The best treatment for cancer cachexia is cancer remission. There are no approved medications for the management of cachexia, and nutritional support alone is inadequate. Combinations of exercise, nutritional support, medications to stimulate appetite (e.g., megestrol acetate, olanzapine), and anti-inflammatories (e.g., celecoxib, omega-3 fatty acids) in small randomized trials have been found to improve outcomes. Mucositis from chemotherapy or radiation therapy is painful, interferes with nutritional intake, is associated with systemic infections and other complications, and increases the length of hospital stay and treatment costs. The evidence for treating mucositis is sparse. Pruritus is a sensation that provokes the desire to scratch. The behavior associated with pruritus extends to the desire to rub or pinch damaged skin with devices. Basic skin care is essential. Treatment of the underlying condition may also ameliorate pruritis. Treatment of the underlying condition may also ameliorate pruritis Lymphoma treatment quickly relieves pruritus related to Hodgkin’s disease and non-Hodgkin’s lymphoma. The classification of hiccups is based on duration. Hiccups are caused by coordinated contractions of intercostal muscle and diaphragm followed by a few milliseconds with involuntary closure of the glottis. Hiccups occur anywhere between 4 and 60 times a minute and can interfere with breathing, eating, and sleep, and can worsen pain, fatigue, weight loss, and dyspnea, dramatically reducing QOL. Pharmacologic management has centered on dopamine, GABA, and serotonin receptors. Dyspnea is a subjective experience of breathing discomfort that consists of qualitatively distinct sensations that include inability to catch one’s breath, ineffective breathing, increased work of breathing, and chest tightness. The correlation of chest radiographic findings and spirometry to dyspnea is quite poor. Treating the underlying cause is the first line of therapy. Low doses of opioids, particularly morphine, and corticosteroid may reduce dyspnea in patients who are imminently dying. The core criteria for delirium comes from the DSM-IV and consists of disturbance of consciousness with loss of the ability to focus and shift attention. Half of patients undergoing hematopoietic stem cell transplants experience delirium during therapy, and the pretransplant risk factors are low cognitive functioning, lower physical functioning, higher creatinine, total body irradiation, older age, and prior alcohol or drug abuse. Prevention of delirium is more successful than treatment of delirium. Anxiety and depression are common symptoms which not only impair quality of life but also makes it difficult managing other symptoms such as pain and fatigue. When considering treatment for depression, both pharmacotherapy and psychotherapy are effective, especially in combination. Psychotherapy is recommended at all stages of depression or anxiety. When pharmacotherapy is considered, prognosis should be evaluated as many medications may take about 4 weeks to reach an effect. The multiplicity of symptoms that occur in advanced hematologic malignancies and other advanced blood disorders is a challenge to hematologists/oncologists. Consideration of palliative care consultation should be considered in patients with high symptom burden.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Homsi J, Walsh D, Rivera N, Rybicki LA, Nelson KA, Legrand SB, et al. Symptom evaluation in palliative medicine: patient report vs systematic assessment. Support Care Cancer. 2006;14(5):444–53.

    Article  PubMed  Google Scholar 

  2. Palm RF, Jim HSL, Boulware D, Johnstone PAS, Naghavi AO. Using the revised Edmonton symptom assessment scale during neoadjuvant radiotherapy for retroperitoneal sarcoma. Clin Transl Radiat Oncol. 2020;22:22–8.

    PubMed  PubMed Central  Google Scholar 

  3. McGee SF, Zhang T, Jonker H, Laurie SA, Goss G, Nicholas G, et al. The impact of baseline Edmonton symptom assessment scale scores on treatment and survival in patients with advanced non-small-cell lung cancer. Clin Lung Cancer. 2018;19(1):e91–e9.

    Article  PubMed  Google Scholar 

  4. Hui D, Shamieh O, Paiva CE, Perez-Cruz PE, Kwon JH, Muckaden MA, et al. Minimal clinically important differences in the Edmonton symptom assessment scale in cancer patients: a prospective, multicenter study. Cancer. 2015;121(17):3027–35.

    Article  PubMed  Google Scholar 

  5. Selby D, Chakraborty A, Myers J, Saskin R, Mazzotta P, Gill A. High scores on the Edmonton symptom assessment scale identify patients with self-defined high symptom burden. J Palliat Med. 2011;14(12):1309–16.

    Article  PubMed  Google Scholar 

  6. Zeng L, Zhang L, Culleton S, Jon F, Holden L, Kwong J, et al. Edmonton symptom assessment scale as a prognosticative indicator in patients with advanced cancer. J Palliat Med. 2011;14(3):337–42.

    Article  PubMed  Google Scholar 

  7. Chang VT, Hwang SS, Feuerman M. Validation of the Edmonton symptom assessment scale. Cancer. 2000;88(9):2164–71.

    Article  CAS  PubMed  Google Scholar 

  8. Oldenmenger WH, de Raaf PJ, de Klerk C, van der Rijt CC. Cut points on 0-10 numeric rating scales for symptoms included in the Edmonton symptom assessment scale in cancer patients: a systematic review. J Pain Symptom Manag. 2013;45(6):1083–93.

    Article  Google Scholar 

  9. Chang VT, Hwang SS, Kasimis B, Thaler HT. Shorter symptom assessment instruments: the condensed memorial symptom assessment scale (CMSAS). Cancer Investig. 2004;22(4):526–36.

    Article  Google Scholar 

  10. Bircan HA, Yalcin GS, Fidanci S, Karaibrahimoglu A, Tuglu HC. The usefulness and prognostic value of memorial symptom assessment-short form and condensed memorial symptom assessment scale in assessment of lung cancer patients. Support Care Cancer. 2020;28(4):2005–14.

    Article  PubMed  Google Scholar 

  11. Ward JA, Balian C, Gilger E, Raybin JL, Li Z, Montgomery KE. Electronic symptom assessment in children and adolescents with advanced cancer undergoing hematopoietic stem cell transplantation. J Pediatr Oncol Nurs. 2020;37(4):255–64.

    Article  PubMed  Google Scholar 

  12. Gerlach C, Taylor K, Ferner M, Munder M, Weber M, Ramsenthaler C. Challenges in the cultural adaptation of the German myeloma patient outcome scale (MyPOS): an outcome measure to support routine symptom assessment in myeloma care. BMC Cancer. 2020;20(1):245.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Cannella L, Caocci G, Jacobs M, Vignetti M, Mandelli F, Efficace F. Health-related quality of life and symptom assessment in randomized controlled trials of patients with leukemia and myelodysplastic syndromes: what have we learned? Crit Rev Oncol Hematol. 2015;96(3):542–54.

    Article  PubMed  Google Scholar 

  14. Chow S, Wan BA, Pidduck W, Zhang L, DeAngelis C, Chan S, et al. Symptoms predictive of overall quality of life using the Edmonton symptom assessment scale in breast cancer patients receiving radiotherapy. Clin Breast Cancer. 2019;19(6):405–10.

    Article  PubMed  Google Scholar 

  15. McKenzie E, Zhang L, Chan S, Zaki P, Razvi Y, Tsao M, et al. Symptom correlates of dyspnea in advanced cancer patients using the Edmonton symptom assessment system. Support Care Cancer. 2020;28(1):87–98.

    Article  PubMed  Google Scholar 

  16. Merchant SJ, Brogly SB, Booth CM, Goldie C, Nanji S, Patel SV, et al. Palliative care and symptom burden in the last year of life: a population-based study of patients with gastrointestinal cancer. Ann Surg Oncol. 2019;26(8):2336–45.

    Article  PubMed  Google Scholar 

  17. Chen JJ, Huang SS, Li IF, Lin KP, Tsay SL. Prognostic association of demographic and clinical factors with the change rates of symptoms and depression among patients with hepatocellular carcinoma. Support Care Cancer. 2019;27(12):4665–74.

    Article  PubMed  Google Scholar 

  18. Berger A, et al. NCCN Guidelines Version 2.2019. Cancer-Related Fatigue 2019. https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/fatigue.pdf.

  19. Manitta V, Zordan R, Cole-Sinclair M, Nandurkar H, Philip J. The symptom burden of patients with hematological malignancy: a cross-sectional observational study. J Pain Symptom Manag. 2011;42(3):432–42.

    Article  Google Scholar 

  20. Hjermstad MJ, Knobel H, Brinch L, Fayers PM, Loge JH, Holte H, et al. A prospective study of health-related quality of life, fatigue, anxiety and depression 3-5 years after stem cell transplantation. Bone Marrow Transplant. 2004;34(3):257–66.

    Article  CAS  PubMed  Google Scholar 

  21. Horsboel TA, Bultmann U, Nielsen CV, Nielsen B, Andersen NT, de Thurah A. Are fatigue, depression and anxiety associated with labour market participation among patients diagnosed with haematological malignancies? A prospective study. Psychooncology. 2015;24(4):408–15.

    Article  PubMed  Google Scholar 

  22. Wang XS. Pathophysiology of cancer-related fatigue. Clin J Oncol Nurs. 2008;12(5 Suppl):11–20.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Fukushima T, Nakano J, Ishii S, Natsuzako A, Kawachi H, Sakamoto J, et al. Influence of hemoglobin level on muscle and physical functions, activities of daily living, and quality of life in patients with hematological malignancies. Integr Cancer Ther. 2019;18:1534735419842196.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Ben-Arye E, Dahan O, Shalom-Sharabi I, Samuels N. Inverse relationship between reduced fatigue and severity of anemia in oncology patients treated with integrative medicine: understanding the paradox. Support Care Cancer. 2018;26(12):4039–48.

    Article  PubMed  Google Scholar 

  25. Monti M, Castellani L, Berlusconi A, Cunietti E. Use of red blood cell transfusions in terminally ill cancer patients admitted to a palliative care unit. J Pain Symptom Manag. 1996;12(1):18–22.

    Article  CAS  Google Scholar 

  26. Kripp M, Willer A, Schmidt C, Pilz LR, Gencer D, Buchheidt D, et al. Patients with malignant hematological disorders treated on a palliative care unit: prognostic impact of clinical factors. Ann Hematol. 2014;93(2):317–25.

    Article  CAS  PubMed  Google Scholar 

  27. Morishita S, Kaida K, Tanaka T, Itani Y, Ikegame K, Okada M, et al. Prevalence of sarcopenia and relevance of body composition, physiological function, fatigue, and health-related quality of life in patients before allogeneic hematopoietic stem cell transplantation. Support Care Cancer. 2012;20(12):3161–8.

    Article  PubMed  Google Scholar 

  28. Scherber RM, Kosiorek HE, Senyak Z, Dueck AC, Clark MM, Boxer MA, et al. Comprehensively understanding fatigue in patients with myeloproliferative neoplasms. Cancer. 2016;122(3):477–85.

    Article  PubMed  Google Scholar 

  29. Prieto JM, Blanch J, Atala J, Carreras E, Rovira M, Cirera E, et al. Clinical factors associated with fatigue in haematologic cancer patients receiving stem-cell transplantation. Eur J Cancer. 2006;42(12):1749–55.

    Article  PubMed  Google Scholar 

  30. Tefferi A, Hudgens S, Mesa R, Gale RP, Verstovsek S, Passamonti F, et al. Use of the Functional Assessment of Cancer Therapy--anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia. Clin Ther. 2014;36(4):560–6.

    Article  PubMed  Google Scholar 

  31. Yang S, Chu S, Gao Y, Ai Q, Liu Y, Li X, et al. A narrative review of cancer-related fatigue (CRF) and its possible pathogenesis. Cell. 2019;8(7):738.

    Article  CAS  Google Scholar 

  32. Filler K, Saligan LN. Defining cancer-related fatigue for biomarker discovery. Support Care Cancer. 2016;24(1):5–7.

    Article  PubMed  Google Scholar 

  33. Fernandez C, Firdous S, Jehangir W, Behm B, Mehta Z, Berger A, et al. Cancer-related fatigue: perception of effort or task failure? Am J Hosp Palliat Care. 2019;37:1049909119849420.

    Google Scholar 

  34. Renner M, Saligan LN. Understanding cancer-related fatigue: advancing the science. Fatigue. 2016;4(4):189–92.

    PubMed  PubMed Central  Google Scholar 

  35. Cai B, Allexandre D, Rajagopalan V, Jiang Z, Siemionow V, Ranganathan VK, et al. Evidence of significant central fatigue in patients with cancer-related fatigue during repetitive elbow flexions till perceived exhaustion. PLoS One. 2014;9(12):e115370.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Kisiel-Sajewicz K, Siemionow V, Seyidova-Khoshknabi D, Davis MP, Wyant A, Ranganathan VK, et al. Myoelectrical manifestation of fatigue less prominent in patients with cancer related fatigue. PLoS One. 2013;8(12):e83636.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Taylor JL, Todd G, Gandevia SC. Evidence for a supraspinal contribution to human muscle fatigue. Clin Exp Pharmacol Physiol. 2006;33(4):400–5.

    Article  CAS  PubMed  Google Scholar 

  38. McComas AJ, Miller RG, Gandevia SC. Fatigue brought on by malfunction of the central and peripheral nervous systems. Adv Exp Med Biol. 1995;384:495–512.

    Article  CAS  PubMed  Google Scholar 

  39. Gandevia SC, Allen GM, McKenzie DK. Central fatigue. Critical issues, quantification and practical implications. Adv Exp Med Biol. 1995;384:281–94.

    Article  CAS  PubMed  Google Scholar 

  40. Zhou ES, Hall KT, Michaud AL, Blackmon JE, Partridge AH, Recklitis CJ. Open-label placebo reduces fatigue in cancer survivors: a randomized trial. Support Care Cancer. 2019;27(6):2179–87.

    Article  PubMed  Google Scholar 

  41. Berenson JR, Yellin O, Shamasunder HK, Chen CS, Charu V, Woliver TB, et al. A phase 3 trial of armodafinil for the treatment of cancer-related fatigue for patients with multiple myeloma. Support Care Cancer. 2015;23(6):1503–12.

    Article  PubMed  Google Scholar 

  42. Mustian KM, Alfano CM, Heckler C, Kleckner AS, Kleckner IR, Leach CR, et al. Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. JAMA Oncol. 2017;3(7):961–8.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Oechsle K, Aslan Z, Suesse Y, Jensen W, Bokemeyer C, de Wit M. Multimodal exercise training during myeloablative chemotherapy: a prospective randomized pilot trial. Support Care Cancer. 2014;22(1):63–9.

    Article  PubMed  Google Scholar 

  44. Dimeo F, Schwartz S, Fietz T, Wanjura T, Boning D, Thiel E. Effects of endurance training on the physical performance of patients with hematological malignancies during chemotherapy. Support Care Cancer. 2003;11(10):623–8.

    Article  PubMed  Google Scholar 

  45. Arring NM, Barton DL, Brooks T, Zick SM. Integrative therapies for cancer-related fatigue. Cancer J. 2019;25(5):349–56.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Yennurajalingam S, Bruera E. Review of clinical trials of pharmacologic interventions for cancer-related fatigue: focus on psychostimulants and steroids. Cancer J. 2014;20(5):319–24.

    Article  CAS  PubMed  Google Scholar 

  47. Qu D, Zhang Z, Yu X, Zhao J, Qiu F, Huang J. Psychotropic drugs for the management of cancer-related fatigue: a systematic review and meta-analysis. Eur J Cancer Care (Engl). 2016;25(6):970–9.

    Article  CAS  PubMed  Google Scholar 

  48. Jean-Pierre P, Morrow GR, Roscoe JA, Heckler C, Mohile S, Janelsins M, et al. A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer. 2010;116(14):3513–20.

    Article  CAS  PubMed  Google Scholar 

  49. Kaplan S, Goehring EL Jr, Melamed-Gal S, Nguyen-Khoa BA, Knebel H, Jones JK. Modafinil and the risk of cardiovascular events: findings from three US claims databases. Pharmacoepidemiol Drug Saf. 2018;27(11):1182–90.

    Article  CAS  PubMed  Google Scholar 

  50. Barton DL, Liu H, Dakhil SR, Linquist B, Sloan JA, Nichols CR, et al. Wisconsin ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. J Natl Cancer Inst. 2013;105(16):1230–8.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Bohlius J, Bohlke K, Castelli R, Djulbegovic B, Lustberg MB, Martino M, et al. Management of Cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. J Clin Oncol. 2019;37(15):1336–51.

    Article  CAS  PubMed  Google Scholar 

  52. Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2012;12:CD003407.

    PubMed  Google Scholar 

  53. Preston NJ, Hurlow A, Brine J, Bennett MI. Blood transfusions for anaemia in patients with advanced cancer. Cochrane Database Syst Rev. 2012;2012(2):CD009007.

    PubMed  PubMed Central  Google Scholar 

  54. Minton O, Richardson A, Sharpe M, Hotopf M, Stone P. Drug therapy for the management of cancer-related fatigue. Cochrane Database Syst Rev. 2010;7:CD006704.

    Google Scholar 

  55. Yennurajalingam S, Frisbee-Hume S, Palmer JL, Delgado-Guay MO, Bull J, Phan AT, et al. Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol. 2013;31(25):3076–82.

    Article  CAS  PubMed  Google Scholar 

  56. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–95.

    Article  PubMed  Google Scholar 

  57. Prado CM, Cushen SJ, Orsso CE, Ryan AM. Sarcopenia and cachexia in the era of obesity: clinical and nutritional impact. Proc Nutr Soc. 2016;75(2):188–98.

    Article  CAS  PubMed  Google Scholar 

  58. Ubachs J, Ziemons J, Minis-Rutten IJG, Kruitwagen R, Kleijnen J, Lambrechts S, et al. Sarcopenia and ovarian cancer survival: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2019;10(6):1165–74.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Sasaki S, Oki E, Saeki H, Shimose T, Sakamoto S, Hu Q, et al. Skeletal muscle loss during systemic chemotherapy for colorectal cancer indicates treatment response: a pooled analysis of a multicenter clinical trial (KSCC 1605-a). Int J Clin Oncol. 2019;24(10):1204–13.

    Article  PubMed  Google Scholar 

  60. Davis MP, Panikkar R. Sarcopenia associated with chemotherapy and targeted agents for cancer therapy. Ann Palliat Med. 2019;8(1):86–101.

    Article  PubMed  Google Scholar 

  61. Tournadre A, Vial G, Capel F, Soubrier M, Boirie Y. Sarcopenia. Joint Bone Spine. 2019;86(3):309–14.

    Article  PubMed  Google Scholar 

  62. Fearon KC. Cancer cachexia and fat-muscle physiology. N Engl J Med. 2011;365(6):565–7.

    Article  CAS  PubMed  Google Scholar 

  63. Yavuzsen T, Walsh D, Davis MP, Kirkova J, Jin T, LeGrand S, et al. Components of the anorexia-cachexia syndrome: gastrointestinal symptom correlates of cancer anorexia. Support Care Cancer. 2009;17(12):1531–41.

    Article  PubMed  Google Scholar 

  64. Davis MP, Walsh D, Lagman R, Yavuzsen T. Early satiety in cancer patients: a common and important but underrecognized symptom. Support Care Cancer. 2006;14(7):693–8.

    Article  PubMed  Google Scholar 

  65. Davis MP, Dreicer R, Walsh D, Lagman R, LeGrand SB. Appetite and cancer-associated anorexia: a review. J Clin Oncol. 2004;22(8):1510–7.

    Article  CAS  PubMed  Google Scholar 

  66. Fearon KC, Barber MD, Falconer JS, McMillan DC, Ross JA, Preston T. Pancreatic cancer as a model: inflammatory mediators, acute-phase response, and cancer cachexia. World J Surg. 1999;23(6):584–8.

    Article  CAS  PubMed  Google Scholar 

  67. Fearon KC, Falconer JS, Slater C, McMillan DC, Ross JA, Preston T. Albumin synthesis rates are not decreased in hypoalbuminemic cachectic cancer patients with an ongoing acute-phase protein response. Ann Surg. 1998;227(2):249–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Mallard J, Gagez AL, Baudinet C, Herbinet A, Maury J, Bernard PL, et al. C-reactive protein level: a key predictive marker of cachexia in lymphoma and myeloma patients. J Hematol. 2019;8(2):55–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Frodin U, Lotfi K, Fomichov V, Juliusson G, Borjeson S. Frequent and long-term follow-up of health-related quality of life following allogeneic haematopoietic stem cell transplantation. Eur J Cancer Care (Engl). 2015;24(6):898–910.

    Article  CAS  PubMed  Google Scholar 

  70. Doney K, McMillen K, Buono L, Deeg HJ, Gooley T. Impact of body mass index on outcomes of hematopoietic stem cell transplantation in adults. Biol Blood Marrow Transplant. 2019;25(3):613–20.

    Article  PubMed  Google Scholar 

  71. Aoyama T, Yoshitsugu K, Fukaya M, Kume T, Kawashima M, Nakajima K, et al. Benefit of reducing body weight loss with a nutritional support pathway in patients undergoing allogeneic hematopoietic stem cell transplantation. Med Sci Monit Basic Res. 2019;25:187–98.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Kerby EH, Li Y, Getz KD, Smith EC, Smith LT, Bunin NJ, et al. Nutritional risk factors predict severe acute graft-versus-host disease and early mortality in pediatric allogeneic hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2018;65(2):e26853.

    Article  Google Scholar 

  73. DeFilipp Z, Troschel FM, Qualls DA, Li S, Kuklinski MW, Kempner ME, et al. Evolution of body composition following autologous and allogeneic hematopoietic cell transplantation: incidence of sarcopenia and association with clinical outcomes. Biol Blood Marrow Transplant. 2018;24(8):1741–7.

    Article  PubMed  Google Scholar 

  74. Silva P, Schmit D, Bonfim C, Campos DJ, Rabito EI, Vilela RM. Body composition of Fanconi anemia patients after hematopoietic stem cell transplantation. Rev Bras Hematol Hemoter. 2017;39(4):318–24.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Cheney CL, Abson KG, Aker SN, Lenssen P, Cunningham BA, Buergel NS, et al. Body composition changes in marrow transplant recipients receiving total parenteral nutrition. Cancer. 1987;59(8):1515–9.

    Article  CAS  PubMed  Google Scholar 

  76. Cunningham BA, Morris G, Cheney CL, Buergel N, Aker SN, Lenssen P. Effects of resistive exercise on skeletal muscle in marrow transplant recipients receiving total parenteral nutrition. JPEN J Parenter Enteral Nutr. 1986;10(6):558–63.

    Article  CAS  PubMed  Google Scholar 

  77. Argiles JM, Lopez-Soriano FJ, Busquets S. Mediators of cachexia in cancer patients. Nutrition. 2019;66:11–5.

    Article  CAS  PubMed  Google Scholar 

  78. Ebner N, Anker SD, von Haehling S. Recent developments in the field of cachexia, sarcopenia, and muscle wasting: highlights from the 11th cachexia conference. J Cachexia Sarcopenia Muscle. 2019;10(1):218–25.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Okabe Y, Sakata T, Kurokawa M, Fujimoto K, Ueda K, Masuno H, et al. Anorexia induced by toxohormone-L isolated from ascites fluid of patients with hepatoma. Physiol Behav. 1992;52(2):333–7.

    Article  CAS  PubMed  Google Scholar 

  80. Penna F, Ballaro R, Beltra M, De Lucia S, Garcia Castillo L, Costelli P. The skeletal muscle as an active player against cancer cachexia. Front Physiol. 2019;10:41.

    Article  PubMed  PubMed Central  Google Scholar 

  81. Barkhudaryan A, Scherbakov N, Springer J, Doehner W. Cardiac muscle wasting in individuals with cancer cachexia. ESC heart Fail. 2017;4(4):458–67.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Roberts BM, Ahn B, Smuder AJ, Al-Rajhi M, Gill LC, Beharry AW, et al. Diaphragm and ventilatory dysfunction during cancer cachexia. FASEB J. 2013;27(7):2600–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Anderson LJ, Yin C, Burciaga R, Lee J, Crabtree S, Migula D, et al. Assessing cachexia acutely after autologous stem cell transplant. Cancers (Basel). 2019;11(9):1300.

    Article  CAS  PubMed  Google Scholar 

  84. Rief W, Mills PJ, Ancoli-Israel S, Ziegler MG, Pung MA, Dimsdale JE. Overnight changes of immune parameters and catecholamines are associated with mood and stress. Psychosom Med. 2010;72(8):755–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Trakada G, Kastritis E, Gavriatopoulou M, Velentza L, Fotiou D, Ziogas DC, et al. Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcome. Ann Hematol. 2019;98(6):1427–34.

    Article  PubMed  Google Scholar 

  86. Mendes NP, Barros TA, Rosa COB, Franceschini S. Nutritional screening tools used and validated for cancer patients: a systematic review. Nutr Cancer. 2019;71(6):898–907.

    Article  PubMed  Google Scholar 

  87. Dolan RD, Daly L, Sim WMJ, Fallon M, Ryan A, McMillan DC, et al. Comparison of the prognostic value of ECOG-PS, mGPS and BMI/WL: implications for a clinically important framework in the assessment and treatment of advanced cancer. Clin Nutr. 2019;39:2889.

    Article  PubMed  Google Scholar 

  88. McDonald JJ, Fallon MT, Laird BJA. Meaningful measures in cancer cachexia: implications for practice and research. Curr Opinion Support Palliative care. 2019;13(4):323–7.

    Article  Google Scholar 

  89. Grundmann O, Yoon SL, Williams JJ. The value of bioelectrical impedance analysis and phase angle in the evaluation of malnutrition and quality of life in cancer patients--a comprehensive review. Eur J Clin Nutr. 2015;69(12):1290–7.

    Article  CAS  PubMed  Google Scholar 

  90. Davis MP, Yavuzsen T, Khoshknabi D, Kirkova J, Walsh D, Lasheen W, et al. Bioelectrical impedance phase angle changes during hydration and prognosis in advanced cancer. Am J Hosp Palliat Care. 2009;26(3):180–7.

    Article  PubMed  Google Scholar 

  91. Roeland EJ, Bohlke K, Baracos VE, Bruera E, Del Fabbro E, Dixon S, et al. Management of cancer cachexia: ASCO guideline. J Clin Oncol. 2020;38:2438.

    Article  CAS  PubMed  Google Scholar 

  92. Miura S, Naito T, Mitsunaga S, Omae K, Mori K, Inano T, et al. A randomized phase II study of nutritional and exercise treatment for elderly patients with advanced non-small cell lung or pancreatic cancer: the NEXTAC-TWO study protocol. BMC Cancer. 2019;19(1):528.

    Article  PubMed  PubMed Central  Google Scholar 

  93. Argiles JM, Lopez-Soriano FJ, Stemmler B, Busquets S. Therapeutic strategies against cancer cachexia. Eur J Transl Myol. 2019;29(1):7960.

    Article  PubMed  PubMed Central  Google Scholar 

  94. Shirai Y, Okugawa Y, Hishida A, Ogawa A, Okamoto K, Shintani M, et al. Fish oil-enriched nutrition combined with systemic chemotherapy for gastrointestinal cancer patients with cancer cachexia. Sci Rep. 2017;7(1):4826.

    Article  PubMed  PubMed Central  Google Scholar 

  95. Ravasco P. Nutrition in cancer patients. J Clin Med. 2019;8(8):1211.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Gorjao R, Dos Santos CMM, Serdan TDA, Diniz VLS, Alba-Loureiro TC, Cury-Boaventura MF, et al. New insights on the regulation of cancer cachexia by N-3 polyunsaturated fatty acids. Pharmacol Ther. 2019;196:117–34.

    Article  CAS  PubMed  Google Scholar 

  97. Okamoto H, Shono K, Nozaki-Taguchi N. Low-dose of olanzapine has ameliorating effects on cancer-related anorexia. Cancer Manag Res. 2019;11:2233–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Crawford J, Prado CM, Johnston MA, Gralla RJ, Taylor RP, Hancock ML, et al. Study design and rationale for the phase 3 clinical development program of enobosarm, a selective androgen receptor modulator, for the prevention and treatment of muscle wasting in cancer patients (POWER trials). Curr Oncol Rep. 2016;18(6):37.

    Article  PubMed  PubMed Central  Google Scholar 

  99. Temel JS, Abernethy AP, Currow DC, Friend J, Duus EM, Yan Y, et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 2016;17(4):519–31.

    Article  CAS  PubMed  Google Scholar 

  100. Duncan M, Grant G. Oral and intestinal mucositis - causes and possible treatments. Aliment Pharmacol Ther. 2003;18(9):853–74.

    Article  CAS  PubMed  Google Scholar 

  101. Kasselberg AG, Orth DN, Gray ME, Stahlman MT. Immunocytochemical localization of human epidermal growth factor/urogastrone in several human tissues. J Histochem Cytochem. 1985;33(4):315–22.

    Article  CAS  PubMed  Google Scholar 

  102. Fujisawa K, Miyamoto Y, Nagayama M. Basic fibroblast growth factor and epidermal growth factor reverse impaired ulcer healing of the rabbit oral mucosa. J Oral Pathol Med. 2003;32(6):358–66.

    Article  CAS  PubMed  Google Scholar 

  103. Epstein JB, Gorsky M, Guglietta A, Le N, Sonis ST. The correlation between epidermal growth factor levels in saliva and the severity of oral mucositis during oropharyngeal radiation therapy. Cancer. 2000;89(11):2258–65.

    Article  CAS  PubMed  Google Scholar 

  104. Schenck K, Schreurs O, Hayashi K, Helgeland K. The role of nerve growth factor (ngf) and its precursor forms in oral wound healing. Int J Mol Sci. 2017;18(2):386.

    Article  PubMed  PubMed Central  Google Scholar 

  105. van Setten GB. Basic fibroblast growth factor in human saliva: detection and physiological implications. Laryngoscope. 1995;105(6):610–2.

    Article  PubMed  Google Scholar 

  106. da Fonseca MA. Management of mucositis in bone marrow transplant patients. J Dent Hyg. 1999;73(1):17–21.

    PubMed  Google Scholar 

  107. McGuire DB, Yeager KA, Dudley WN, Peterson DE, Owen DC, Lin LS, et al. Acute oral pain and mucositis in bone marrow transplant and leukemia patients: data from a pilot study. Cancer Nurs. 1998;21(6):385–93.

    Article  CAS  PubMed  Google Scholar 

  108. Woo SB, Sonis ST, Monopoli MM, Sonis AL. A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer. 1993;72(5):1612–7.

    Article  CAS  PubMed  Google Scholar 

  109. Zerbe MB, Parkerson SG, Ortlieb ML, Spitzer T. Relationships between oral mucositis and treatment variables in bone marrow transplant patients. Cancer Nurs. 1992;15(3):196–205.

    Article  CAS  PubMed  Google Scholar 

  110. Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer. 2004;100(9 Suppl):2026–46.

    Article  PubMed  Google Scholar 

  111. Logan RM, Stringer AM, Bowen JM, Gibson RJ, Sonis ST, Keefe DM. Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered? Cancer Chemother Pharmacol. 2009;63(2):239–51.

    Article  CAS  PubMed  Google Scholar 

  112. Logan RM, Gibson RJ, Bowen JM, Stringer AM, Sonis ST, Keefe DM. Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol. 2008;62(1):33–41.

    Article  CAS  PubMed  Google Scholar 

  113. Lambros MP, Parsa C, Mulamalla H, Orlando R, Lau B, Huang Y, et al. Identifying cell and molecular stress after radiation in a three-dimensional (3-D) model of oral mucositis. Biochem Biophys Res Commun. 2011;405(1):102–6.

    Article  CAS  PubMed  Google Scholar 

  114. Hong BY, Sobue T, Choquette L, Dupuy AK, Thompson A, Burleson JA, et al. Chemotherapy-induced oral mucositis is associated with detrimental bacterial dysbiosis. Microbiome. 2019;7(1):66.

    Article  PubMed  PubMed Central  Google Scholar 

  115. Basile D, Di Nardo P, Corvaja C, Garattini SK, Pelizzari G, Lisanti C, et al. Mucosal injury during anti-cancer treatment: from pathobiology to bedside. Cancer. 2019;11(6):857.

    Article  CAS  Google Scholar 

  116. Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004;100(9 Suppl):1995–2025.

    Article  PubMed  Google Scholar 

  117. Maria OM, Eliopoulos N, Muanza T. Radiation-induced Oral mucositis. Front Oncol. 2017;7:89.

    Article  PubMed  PubMed Central  Google Scholar 

  118. Hong CHL, Gueiros LA, Fulton JS, Cheng KKF, Kandwal A, Galiti D, et al. Systematic review of basic oral care for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer. 2019;27(10):3949–67.

    Article  PubMed  Google Scholar 

  119. Wilairat P, Kengkla K, Kaewpanan T, Kaewthong J, Ruankon S, Subthaweesin C, et al. Comparative efficacy and safety of interventions for preventing chemotherapy-induced oral mucositis in adult cancer patients: a systematic review and network meta-analysis. Eur J Hosp Pharm. 2020;27(2):103–10.

    Article  PubMed  Google Scholar 

  120. Bowen JM, Wardill HR. Advances in the understanding and management of mucositis during stem cell transplantation. Curr Opin Support Palliat Care. 2017;11(4):341–6.

    Article  PubMed  Google Scholar 

  121. Ariyawardana A, Cheng KKF, Kandwal A, Tilly V, Al-Azri AR, Galiti D, et al. Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer. 2019;27(10):3985–95.

    Article  PubMed  Google Scholar 

  122. Okamoto K, Ninomiya I, Yamaguchi T, Terai S, Nakanuma S, Kinoshita J, et al. Oral cryotherapy for prophylaxis of oral mucositis caused by docetaxel, cisplatin, and fluorouracil chemotherapy for esophageal cancer. Esophagus: official journal of the Japan esophageal. Society. 2019;16(2):207–13.

    Google Scholar 

  123. Correa MEP, Cheng KKF, Chiang K, Kandwal A, Loprinzi CL, Mori T, et al. Systematic review of oral cryotherapy for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer. 2020;28(5):2449–56.

    Article  PubMed  Google Scholar 

  124. Sherr DL. Finding the magic in magic mouthwash. JAMA Intern Med. 2019;179(5):723–4.

    Article  PubMed  Google Scholar 

  125. Carnel SB, Blakeslee DB, Oswald SG, Barnes M. Treatment of radiation- and chemotherapy-induced stomatitis. Otolaryngol Head Neck Surg. 1990;102(4):326–30.

    Article  CAS  PubMed  Google Scholar 

  126. Milazzo-Kiedaisch CA, Itano J, Dutta PR. Role of gabapentin in managing mucositis pain in patients undergoing radiation therapy to the head and neck. Clin J Oncol Nurs. 2016;20(6):623–8.

    Article  PubMed  PubMed Central  Google Scholar 

  127. Kataoka T, Kiyota N, Shimada T, Funakoshi Y, Chayahara N, Toyoda M, et al. Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer. Auris Nasus Larynx. 2016;43(6):677–84.

    Article  PubMed  Google Scholar 

  128. Bar AV, Weinstein G, Dutta PR, Dosoretz A, Chalian A, Both S, et al. Gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck cancer treated with concurrent chemoradiotherapy. Cancer. 2010;116(17):4206–13.

    Article  Google Scholar 

  129. Bar AV, Weinstein G, Dutta PR, Chalian A, Both S, Quon H. Gabapentin for the treatment of pain related to radiation-induced mucositis in patients with head and neck tumors treated with intensity-modulated radiation therapy. Head Neck. 2010;32(2):173–7.

    Article  Google Scholar 

  130. Hermann GM, Iovoli AJ, Platek AJ, Wang C, Miller A, Attwood K, et al. A single-institution, randomized, pilot study evaluating the efficacy of gabapentin and methadone for patients undergoing chemoradiation for head and neck squamous cell cancer. Cancer. 2020;126(7):1480–91.

    Article  CAS  PubMed  Google Scholar 

  131. Elad S, Meidan I, Sellam G, Simaan S, Zeevi I, Waldman E, et al. Topical curcumin for the prevention of oral mucositis in pediatric patients: case series. Altern Ther Health Med. 2013;19(3):21–4.

    PubMed  Google Scholar 

  132. Dos Reis PE, Ciol MA, de Melo NS, Figueiredo PT, Leite AF, Manzi NM. Chamomile infusion cryotherapy to prevent oral mucositis induced by chemotherapy: a pilot study. Support Care Cancer. 2016;24(10):4393–8.

    Article  PubMed  Google Scholar 

  133. Sahebjamee M, Mansourian A, Hajimirzamohammad M, Zadeh MT, Bekhradi R, Kazemian A, et al. Comparative efficacy of aloe vera and benzydamine mouthwashes on radiation-induced oral mucositis: a triple-blind, randomised, controlled clinical trial. Oral Health Prev Dent. 2015;13(4):309–15.

    PubMed  Google Scholar 

  134. Liu TM, Luo YW, Tam KW, Lin CC, Huang TW. Prophylactic and therapeutic effects of honey on radiochemotherapy-induced mucositis: a meta-analysis of randomized controlled trials. Support Care Cancer. 2019;27(7):2361–70.

    Article  PubMed  Google Scholar 

  135. Zecha JA, Raber-Durlacher JE, Nair RG, Epstein JB, Sonis ST, Elad S, et al. Low level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 1: mechanisms of action, dosimetric, and safety considerations. Support Care Cancer. 2016;24(6):2781–92.

    Article  PubMed  PubMed Central  Google Scholar 

  136. Cronshaw M, Parker S, Anagnostaki E, Mylona V, Lynch E, Grootveld M. Photobiomodulation and oral mucositis: a systematic review. Dent J (Basel). 2020;8(3):87.

    Article  PubMed  Google Scholar 

  137. Elad S, Cheng KKF, Lalla RV, Yarom N, Hong C, Logan RM, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2020;126:4423.

    Article  PubMed  Google Scholar 

  138. Zadik Y, Arany PR, Fregnani ER, Bossi P, Antunes HS, Bensadoun RJ, et al. Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer. 2019;27(10):3969–83.

    Article  PubMed  Google Scholar 

  139. Stander S. Chronic pruritus: principals of diagnostics and therapy. Hautarzt. 2007;58(7):627–36. quiz 37

    CAS  PubMed  Google Scholar 

  140. Matterne U, Apfelbacher CJ, Loerbroks A, Schwarzer T, Buttner M, Ofenloch R, et al. Prevalence, correlates and characteristics of chronic pruritus: a population-based cross-sectional study. Acta Derm Venereol. 2011;91(6):674–9.

    Article  PubMed  Google Scholar 

  141. Alizadeh N, Mirpour SH, Golmohamadi R, Darjani A, Eftekhari H, Rafiei R, et al. Chronic generalized pruritus without primary skin lesions: a longitudinal prospective observational study. Int J Dermatol. 2019;58(3):273–8.

    Article  PubMed  Google Scholar 

  142. Larson VA, Tang O, Stander S, Kang S, Kwatra SG. Association between itch and cancer in 16,925 patients with pruritus: experience at a tertiary care center. J Am Acad Dermatol. 2019;80(4):931–7.

    Article  PubMed  Google Scholar 

  143. Beigi M, Haberle M, Gschwendtner A, Baum U, Weisshaar E. Generalized chronic itch as a first sign of malignancy resembling paraneoplastic sensomotoric neuropathy. Acta Derm Venereol. 2018;98(5):526–7.

    Article  PubMed  Google Scholar 

  144. Song A, Gochoco A, Zhan T, Sahu J, Alpdogan O, Porcu P, et al. A prospective cohort study of condensed low-dose total skin electron beam therapy for mycosis fungoides: reduction of disease burden and improvement in quality of life. J Am Acad Dermatol. 2020;83(1):78–85.

    Article  CAS  PubMed  Google Scholar 

  145. Bromberg H, Chang Y, Craig D. Pruritic manifestation of peripheral t cell lymphoma effectively managed with mirtazapine: a case report. J Pain Palliat Care Pharmacother. 2020;34(3):153–4.

    Article  PubMed  Google Scholar 

  146. Molloy K, Jonak C, Woei AJF, Guenova E, Busschots AM, Bervoets A, et al. Characteristics associated with significantly worse quality of life in mycosis fungoides/Sezary syndrome from the prospective cutaneous lymphoma international prognostic index (PROCLIPI) study. Br J Dermatol. 2020;182(3):770–9.

    Article  CAS  PubMed  Google Scholar 

  147. Luman W, Cull A, Palmer KR. Quality of life in patients stented for malignant biliary obstructions. Eur J Gastroenterol Hepatol. 1997;9(5):481–4.

    Article  CAS  PubMed  Google Scholar 

  148. Ballinger AB, McHugh M, Catnach SM, Alstead EM, Clark ML. Symptom relief and quality of life after stenting for malignant bile duct obstruction. Gut. 1994;35(4):467–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  149. Elford AT, Dwyer JP, Fanning SB. Jaundice, hepatosplenomegaly, and portal lymphadenopathy in a middle-aged female: is it lymphoma? JGH Open. 2020;4(2):292–3.

    Article  PubMed  Google Scholar 

  150. Szepietowski JC, Salomon J. Uremic pruritus: still an important clinical problem. J Am Acad Dermatol. 2004;51(5):842–3.

    Article  PubMed  Google Scholar 

  151. Enk CD, Elad S, Vexler A, Kapelushnik J, Gorodetsky R, Kirschbaum M. Chronic graft-versus-host disease treated with UVB phototherapy. Bone Marrow Transplant. 1998;22(12):1179–83.

    Article  CAS  PubMed  Google Scholar 

  152. Mochel MC, Ming ME, Imadojemu S, Gangadhar TC, Schuchter LM, Elenitsas R, et al. Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma. J Cutan Pathol. 2016;43(9):787–91.

    Article  PubMed  Google Scholar 

  153. Kilic A, Gul U, Soylu S. Skin findings in internal malignant diseases. Int J Dermatol. 2007;46(10):1055–60.

    Article  PubMed  Google Scholar 

  154. Steinman HK, Greaves MW. Aquagenic pruritus. J Am Acad Dermatol. 1985;13(1):91–6.

    Article  CAS  PubMed  Google Scholar 

  155. Barnes HM, Sarkany I, Calnan CD. Pruritus and thyrotoxicosis. Trans St Johns Hosp Dermatol Soc. 1974;60(1):59–62.

    CAS  PubMed  Google Scholar 

  156. Barrow MV, Bird ED. Pruritus in hyperthyroidism. Arch Dermatol. 1966;93(2):237–8.

    Article  CAS  PubMed  Google Scholar 

  157. Papathanasiou IV, Kelepouris K, Valari C, Papagiannis D, Tzavella F, Kourkouta L, et al. Depression, anxiety and stress among patients with hematological malignancies and the association with quality of life: a cross-sectional study. Med Pharm Rep. 2020;93(1):62–8.

    PubMed  PubMed Central  Google Scholar 

  158. Stander S, Weisshaar E, Mettang T, Szepietowski JC, Carstens E, Ikoma A, et al. Clinical classification of itch: a position paper of the international forum for the study of itch. Acta Derm Venereol. 2007;87(4):291–4.

    Article  PubMed  Google Scholar 

  159. Huang AH, Kaffenberger BH, Reich A, Szepietowski JC, Stander S, Kwatra SG. Pruritus associated with commonly prescribed medications in a tertiary care center. Medicine. 2019;6(3):84.

    CAS  Google Scholar 

  160. Peters J. Medication-related pruritis in older adults with long-term conditions. Br J Community Nurs. 2019;24(8):380–2.

    Article  PubMed  Google Scholar 

  161. Nocchi L, Roy N, D'Attilia M, Dhandapani R, Maffei M, Traista A, et al. Interleukin-31-mediated photoablation of pruritogenic epidermal neurons reduces itch-associated behaviours in mice. Nat Biomed Eng. 2019;3(2):114–25.

    Article  CAS  PubMed  Google Scholar 

  162. Tsuji M, Arai I, Miyagawa K, Miyagishi H, Saito A, Takeda K, et al. Involvement of interleukin-31 receptor a in morphine-induced itching and antinociception in mice. Eur J Pain. 2019;23(2):378–88.

    Article  CAS  PubMed  Google Scholar 

  163. Steinman HK, Kobza-Black A, Lotti TM, Brunetti L, Panconesi E, Greaves MW. Polycythaemia rubra vera and water-induced pruritus: blood histamine levels and cutaneous fibrinolytic activity before and after water challenge. Br J Dermatol. 1987;116(3):329–33.

    Article  CAS  PubMed  Google Scholar 

  164. Shah RA, Kowdley KV. Mechanisms and treatments of pruritus in primary biliary cholangitis. Semin Liver Dis. 2019;39(2):209–20.

    Article  CAS  PubMed  Google Scholar 

  165. Weisshaar E, Szepietowski JC, Dalgard FJ, Garcovich S, Gieler U, Gimenez-Arnau AM, et al. European S2k guideline on chronic pruritus. Acta Derm Venereol. 2019;99(5):469–506.

    Article  PubMed  Google Scholar 

  166. Krause K, Kessler B, Weller K, Veidt J, Chen SC, Martus P, et al. German version of ItchyQoL: validation and initial clinical findings. Acta Derm Venereol. 2013;93(5):562–8.

    Article  PubMed  Google Scholar 

  167. Lindh JD, Bradley M. Clinical effectiveness of moisturizers in atopic dermatitis and related disorders: a systematic review. Am J Clin Dermatol. 2015;16(5):341–59.

    Article  PubMed  Google Scholar 

  168. Rukwied R, Watkinson A, McGlone F, Dvorak M. Cannabinoid agonists attenuate capsaicin-induced responses in human skin. Pain. 2003;102(3):283–8.

    Article  CAS  PubMed  Google Scholar 

  169. Cedeno-Laurent F, Singer EM, Wysocka M, Benoit BM, Vittorio CC, Kim EJ, et al. Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities. Clin Immunol. 2015;158(1):1–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  170. Wolfhagen FH, Sternieri E, Hop WC, Vitale G, Bertolotti M, Van Buuren HR. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology. 1997;113(4):1264–9.

    Article  CAS  PubMed  Google Scholar 

  171. Kwatra SG, Stander S, Kang H. PD-1 blockade-induced pruritus treated with a mu-opioid receptor antagonist. N Engl J Med. 2018;379(16):1578–9.

    Article  PubMed  Google Scholar 

  172. Mozer-Glassberg Y, Hojsak I, Zevit N, Shapiro R, Shamir R. Pruritus responsive to naltrexone in a patient with cholestatic liver disease. Isr Medi Assoc J. 2011;13(2):111–2.

    Google Scholar 

  173. Mettang M, Weisshaar E. Pruritus: control of itch in patients undergoing dialysis. Skin Therapy Lett. 2010;15(2):1–5.

    CAS  PubMed  Google Scholar 

  174. Reszke R, Szepietowski JC. End-stage renal disease chronic itch and its management. Dermatol Clin. 2018;36(3):277–92.

    Article  CAS  PubMed  Google Scholar 

  175. Razeghi E, Eskandari D, Ganji MR, Meysamie AP, Togha M, Khashayar P. Gabapentin and uremic pruritus in hemodialysis patients. Ren Fail. 2009;31(2):85–90.

    Article  CAS  PubMed  Google Scholar 

  176. Manenti L, Vaglio A, Costantino E, Danisi D, Oliva B, Pini S, et al. Gabapentin in the treatment of uremic itch: an index case and a pilot evaluation. J Nephrol. 2005;18(1):86–91.

    CAS  PubMed  Google Scholar 

  177. Simonsen E, Komenda P, Lerner B, Askin N, Bohm C, Shaw J, et al. Treatment of uremic pruritus: a systematic review. Am J Kidney Dis. 2017;70(5):638–55.

    Article  CAS  PubMed  Google Scholar 

  178. Ataei S, Kord L, Larki A, Yasrebifar F, Mehrpooya M, Seyedtabib M, et al. Comparison of sertraline with rifampin in the treatment of cholestatic pruritus: a randomized clinical trial. Rev Recent Clin Trials. 2019;14(3):217–23.

    Article  CAS  PubMed  Google Scholar 

  179. Roulet T, Zdanowicz N. Delusional parasitosis treated by atypical antipsychotic and selective serotonin reuptake inhibitor: a case report. Psychiatr Danub. 2017;29(Suppl 3):219–21.

    PubMed  Google Scholar 

  180. Greaves MW. Itch in systemic disease: therapeutic options. Dermatol Ther. 2005;18(4):323–7.

    Article  PubMed  Google Scholar 

  181. Gupta MA, Guptat AK. The use of antidepressant drugs in dermatology. J Eur Acad Dermatol Venereol. 2001;15(6):512–8.

    Article  CAS  PubMed  Google Scholar 

  182. Khanna R, Boozalis E, Belzberg M, Zampella JG, Kwatra SG. Mirtazapine for the treatment of chronic pruritus. Medicine. 2019;6(3):73.

    CAS  Google Scholar 

  183. Kaur R, Sinha VR. Antidepressants as antipruritic agents: a review. Eur Neuropsychopharmacol. 2018;28(3):341–52.

    Article  CAS  PubMed  Google Scholar 

  184. Kouwenhoven TA, van de Kerkhof PCM, Kamsteeg M. Use of oral antidepressants in patients with chronic pruritus: a systematic review. J Am Acad Dermatol. 2017;77(6):1068–73 e7.

    Article  CAS  PubMed  Google Scholar 

  185. Demierre MF, Taverna J. Mirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphoma. J Am Acad Dermatol. 2006;55(3):543–4.

    Article  PubMed  Google Scholar 

  186. Davis MP, Frandsen JL, Walsh D, Andresen S, Taylor S. Mirtazapine for pruritus. J Pain Symptom Manag. 2003;25(3):288–91.

    Article  Google Scholar 

  187. Rashid S, Trivedi DD, Al-Shathir M, Moulton M, Baumrucker SJ. Is there a role for 5-HT3 receptor antagonists in the treatment of opioid-induced pruritus? Am J Hosp Palliat Care. 2018;35(4):740–4.

    Article  PubMed  Google Scholar 

  188. Muller C, Pongratz S, Pidlich J, Penner E, Kaider A, Schemper M, et al. Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol. 1998;10(10):865–70.

    Article  CAS  PubMed  Google Scholar 

  189. O'Donohue JW, Pereira SP, Ashdown AC, Haigh CG, Wilkinson JR, Williams R. A controlled trial of ondansetron in the pruritus of cholestasis. Aliment Pharmacol Ther. 2005;21(8):1041–5.

    Article  CAS  PubMed  Google Scholar 

  190. Swarna SS, Aziz K, Zubair T, Qadir N, Khan M. Pruritus associated with chronic kidney disease: a comprehensive literature review. Cureus. 2019;11(7):e5256.

    PubMed  PubMed Central  Google Scholar 

  191. Hussain AB, Samuel R, Hegade VS, Jones DE, Reynolds NJ. Pruritus secondary to primary biliary cholangitis: a review of the pathophysiology and management with phototherapy. Br J Dermatol. 2019;181(6):1138–45.

    Article  CAS  PubMed  Google Scholar 

  192. Inan S, Torres-Huerta A, Jensen LE, Dun NJ. Yy a kappa opioid receptor agonist and mu opioid receptor antagonist attenuates pruritus, decreases IL-31, and increases IL-10 in mice with contact dermatitis. Eur J Pharmacol. 2019;864:172702.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  193. Mercadante S. Opioid analgesics adverse effects: the other side of the coin. Curr Pharm Des. 2019;25(30):3197–202.

    Article  CAS  PubMed  Google Scholar 

  194. Tubog TD, Harenberg JL, Buszta K, Hestand JD. Prophylactic Nalbuphine to prevent Neuraxial opioid-induced pruritus: a systematic review and meta-analysis of randomized controlled trials. J Perianesth Nurs. 2019;34(3):491–501 e8.

    Article  PubMed  Google Scholar 

  195. Lewis JH. Hiccups: causes and cures. J Clin Gastroenterol. 1985;7(6):539–52.

    Article  CAS  PubMed  Google Scholar 

  196. Steger M, Schneemann M, Fox M. Systemic review: the pathogenesis and pharmacological treatment of hiccups. Aliment Pharmacol Ther. 2015;42(9):1037–50.

    Article  CAS  PubMed  Google Scholar 

  197. Kohse EK, Hollmann MW, Bardenheuer HJ, Kessler J. Chronic hiccups: an underestimated problem. Anesth Analg. 2017;125(4):1169–83.

    Article  PubMed  Google Scholar 

  198. Chang FY, Lu CL. Hiccup: mystery, nature and treatment. J Neurogastroenterol Motil. 2012;18(2):123–30.

    Article  PubMed  PubMed Central  Google Scholar 

  199. Jeon YS, Kearney AM, Baker PG. Management of hiccups in palliative care patients. BMJ Support Palliat Care. 2018;8(1):1–6.

    Article  PubMed  Google Scholar 

  200. Woelk CJ. Managing hiccups. Can Fam Physician. 2011;57(6):672–5. e198-201

    PubMed  PubMed Central  Google Scholar 

  201. Gilbar P, McPherson I. Severe hiccups during chemotherapy: corticosteroids the likely culprit. J Oncol Pharm Pract. 2009;15(4):233–6.

    Article  CAS  PubMed  Google Scholar 

  202. Zhou JN, Huang XE, Ye Z, Li C, Zhang Q, Lin Y, et al. Weekly paclitaxel/ docetaxel combined with a platinum in the treatment of advanced non-small cell lung cancer: a study on efficacy, safety and pre-medication. Asian Pac J Cancer Prev. 2009;10(6):1147–50.

    PubMed  Google Scholar 

  203. Forghieri F, Maccaferri M, Morselli M, Potenza L, Volzone F, Bandieri E, et al. Persistent hiccups as an adverse event to FLAG-IDA regimen for leukemia. Acta Oncol. 2009;48(6):932–3.

    Article  PubMed  Google Scholar 

  204. Takiguchi Y, Watanabe R, Nagao K, Kuriyama T. Hiccups as an adverse reaction to cancer chemotherapy. J Natl Cancer Inst. 2002;94(10):772.

    Article  CAS  PubMed  Google Scholar 

  205. Engleman EG, Lankton J, Lankton B. Granulated sugar as treatment for hiccups in conscious patients. N Engl J Med. 1971;285(26):1489.

    Article  CAS  PubMed  Google Scholar 

  206. Nausheen F, Mohsin H, Lakhan SE. Neurotransmitters in hiccups. Springerplus. 2016;5(1):1357.

    Article  PubMed  PubMed Central  Google Scholar 

  207. Wang T, Wang D. Metoclopramide for patients with intractable hiccups: a multicentre, randomised, controlled pilot study. Intern Med J. 2014;44(12a):1205–9.

    Article  CAS  PubMed  Google Scholar 

  208. Zhang C, Zhang R, Zhang S, Xu M, Zhang S. Baclofen for stroke patients with persistent hiccups: a randomized, double-blind, placebo-controlled trial. Trials. 2014;15:295.

    Article  PubMed  PubMed Central  Google Scholar 

  209. Curcic J, Schwizer A, Kaufman E, Forras-Kaufman Z, Banerjee S, Roy S, et al. Effects of baclofen on the functional anatomy of the oesophago-gastric junction and proximal stomach in healthy volunteers and patients with GERD assessed by magnetic resonance imaging and high-resolution manometry: a randomised controlled double-blind study. Aliment Pharmacol Ther. 2014;40(10):1230–40.

    Article  CAS  PubMed  Google Scholar 

  210. Holloway RH, Boeckxstaens GE, Penagini R, Sifrim D, Smout AJ. Objective definition and detection of transient lower esophageal sphincter relaxation revisited: is there room for improvement? Neurogastroenterol Motil. 2012;24(1):54–60.

    Article  CAS  PubMed  Google Scholar 

  211. Lehmann A, Hansson-Branden L, Karrberg L. Effects of repeated administration of baclofen on transient lower esophageal sphincter relaxation in the dog. Eur J Pharmacol. 2000;403(1–2):163–7.

    Article  CAS  PubMed  Google Scholar 

  212. Ozturk O, Yavuz E, Yazicioglu B, Uzuner B. Treatment of resistant idiopathic hiccups with pulse radio frequency on phrenic nerve and gabapentin: a case report. Niger J Clin Pract. 2017;20(7):910–3.

    Article  CAS  PubMed  Google Scholar 

  213. Ong AM, Tan CS, Foo MW, Kee TY. Gabapentin for intractable hiccups in a patient undergoing peritoneal dialysis. Perit Dial Int. 2008;28(6):667–8.

    Article  PubMed  Google Scholar 

  214. Tegeler ML, Baumrucker SJ. Gabapentin for intractable hiccups in palliative care. Am J Hosp Palliat Care. 2008;25(1):52–4.

    Article  PubMed  Google Scholar 

  215. Dong R, Xu X, Yu L, Ding H, Pan J, Yu Y, et al. Randomised clinical trial: gabapentin vs baclofen in the treatment of suspected refractory gastro-oesophageal reflux-induced chronic cough. Aliment Pharmacol Ther. 2019;49(6):714–22.

    Article  CAS  PubMed  Google Scholar 

  216. Polito NB, Fellows SE. Pharmacologic interventions for intractable and persistent hiccups: a systematic review. J Emerg Med. 2017;53(4):540–9.

    Article  PubMed  Google Scholar 

  217. Adam E. A systematic review of the effectiveness of Oral baclofen in the Management of Hiccups in adult palliative care patients. J Pain Palliat Care Pharmacother. 2020;34(1):43–54.

    Article  PubMed  Google Scholar 

  218. Rouse S, Wodziak M. Intractable Hiccups. Curr Neurol Neurosci Rep. 2018;18(8):51.

    Article  PubMed  Google Scholar 

  219. Dyspnea. Mechanisms, assessment, and management: a consensus statement. American Thoracic Society. Am J Respir Crit Care Med. 1999;159(1):321–40.

    Article  Google Scholar 

  220. Banzett RBB, Sheridan AR, Baker KM, Lansing RW, Stevens JP. Scared to death' dyspnoea from the hospitalised patient's perspective. BMJ Open Pespir Res. 2020;7(1):e000493.

    Article  Google Scholar 

  221. Bruera E, Schmitz B, Pither J, Neumann CM, Hanson J. The frequency and correlates of dyspnea in patients with advanced cancer. J Pain Symptom Manag. 2000;19(5):357–62.

    Article  CAS  Google Scholar 

  222. Arigliani M, Gupta A. Management of chronic respiratory complications in children and adolescents with sickle cell disease. Eur Respir Rev. 2020;29(157):200054.

    Article  PubMed  PubMed Central  Google Scholar 

  223. Alameri HF, Aleem A, Kardas W, Jehangir A, Owais M, Al-Momen A. Dyspnea, pulmonary function and exercise capacity in adult Saudi patients with sickle cell disease. Saudi Med J. 2008;29(5):707–13.

    PubMed  Google Scholar 

  224. Bosnak Guclu M, Bargi G, Sucak GT. Impairments in dyspnea, exercise capacity, physical activity and quality of life of allogeneic hematopoietic stem cell transplantation survivors compared with healthy individuals: a cross sectional study. Physiother Theory Pract. 2019;37:1–12.

    Google Scholar 

  225. Roberts MH, Mapel DW, Bruse S, Petersen H, Nyunoya T. Development of a modified BODE index as a mortality risk measure among older adults with and without chronic obstructive pulmonary disease. Am J Epidemiol. 2013;178(7):1150–60.

    Article  PubMed  PubMed Central  Google Scholar 

  226. Ueno R, Nemoto M, Uegami W, Fukuoka J, Misawa M. Pembrolizumab-induced pneumonitis with a perilymphatic nodular pattern in a lung cancer patient: a radio-pathologic correlation. Respir Med Case Rep. 2019;26:168–70.

    PubMed  PubMed Central  Google Scholar 

  227. Tateishi A, Nakashima K, Hoshi K, Oyama Y, Ebisudani T, Misawa M, et al. Pulmonary tumor thrombotic Microangiopathy mimicking inhalation lung injury. Intern Med. 2019;58(9):1311–4.

    Article  PubMed  PubMed Central  Google Scholar 

  228. Kazemi-Bajestani SMR, Becher H, Butts C, Basappa NS, Smylie M, Joy AA, et al. Undiagnosed cardiac deficits in non-small cell carcinoma patients in the candidate population for anti-cachexia clinical trials. Support Care Cancer. 2019;27(4):1551–61.

    Article  PubMed  Google Scholar 

  229. Hecimovic A, Jakopovic M, Vukic Dugac A, Dzubur F, Samarzija M. Metastatic cancer mimics interstitial lung disease. Cases when we need fast diagnosis and treatment. Monaldi archives for chest disease. 2019;89(2)

    Google Scholar 

  230. Stana F, Vujovic M, Mayaki D, Leduc-Gaudet JP, Leblanc P, Huck L, et al. Differential regulation of the autophagy and proteasome pathways in skeletal muscles in sepsis. Crit Care Med. 2017;45(9):e971–e9.

    Article  CAS  PubMed  Google Scholar 

  231. Travers J, Dudgeon DJ, Amjadi K, McBride I, Dillon K, Laveneziana P, et al. Mechanisms of exertional dyspnea in patients with cancer. J Appl Physiol. 2008;104(1):57–66.

    Article  CAS  PubMed  Google Scholar 

  232. Sjoland H, Caidahl K, Karlson BW, Karlsson T, Herlitz J. Limitation of physical activity, dyspnea and chest pain before and two years after coronary artery bypass grafting in relation to sex. Int J Cardiol. 1997;61(2):123–33.

    Article  CAS  PubMed  Google Scholar 

  233. O'Donnell DE, Milne KM, James MD, de Torres JP, Neder JA. Dyspnea in COPD: new mechanistic insights and management implications. Adv Ther. 2020;37(1):41–60.

    Article  PubMed  Google Scholar 

  234. Reijnders T, Troosters T, Janssens W, Gosselink R, Langer D, Davenport PW, et al. Brain activations to Dyspnea in patients with COPD. Front Physiol. 2020;11:7.

    Article  PubMed  PubMed Central  Google Scholar 

  235. Schon D, Dahme B, von Leupoldt A. Associations between the perception of dyspnea, pain, and negative affect. Psychophysiology. 2008;45(6):1064–7.

    Article  PubMed  Google Scholar 

  236. Nakai H, Tsujimoto K, Fuchigami T, Ohmatsu S, Osumi M, Nakano H, et al. Effect of anticipation triggered by a prior dyspnea experience on brain activity. J Phys Ther Sci. 2015;27(3):635–9.

    Article  PubMed  PubMed Central  Google Scholar 

  237. von Leupoldt A, Sommer T, Kegat S, Baumann HJ, Klose H, Dahme B, et al. The unpleasantness of perceived dyspnea is processed in the anterior insula and amygdala. Am J Respir Crit Care Med. 2008;177(9):1026–32.

    Article  Google Scholar 

  238. Gandevia SC, Killian K, McKenzie DK, Crawford M, Allen GM, Gorman RB, et al. Respiratory sensations, cardiovascular control, kinaesthesia and transcranial stimulation during paralysis in humans. J Physiol. 1993;470:85–107.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  239. Dudgeon DJ, Lertzman M, Askew GR. Physiological changes and clinical correlations of dyspnea in cancer outpatients. J Pain Symptom Manag. 2001;21(5):373–9.

    Article  CAS  Google Scholar 

  240. Hui D, Morgado M, Vidal M, Withers L, Nguyen Q, Chisholm G, et al. Dyspnea in hospitalized advanced cancer patients: subjective and physiologic correlates. J Palliat Med. 2013;16(3):274–80.

    Article  PubMed  PubMed Central  Google Scholar 

  241. Kuyucu T, Guclu SZ, Saylan B, Demir C, Senol T, Guner S, et al. A cross-sectional observational study to investigate daily symptom variability, effects of symptom on morning activities and therapeutic expectations of patients and physicians in COPD-SUNRISE study. Tuberkuloz ve toraks. 2011;59(4):328–39.

    Article  PubMed  Google Scholar 

  242. Berliner D, Schneider N, Welte T, Bauersachs J. The differential diagnosis of Dyspnea. Dtsch Arztebl Int. 2016;113(49):834–45.

    PubMed  PubMed Central  Google Scholar 

  243. Morris NR, Sabapathy S, Adams L, Kingsley RA, Schneider DA, Stulbarg MS. Verbal numerical scales are as reliable and sensitive as visual analog scales for rating dyspnea in young and older subjects. Respir Physiol Neurobiol. 2007;157(2–3):360–5.

    Article  CAS  PubMed  Google Scholar 

  244. Farncombe M. Dyspnea: assessment and treatment. Support Care Cancer. 1997;5(2):94–9.

    Article  CAS  PubMed  Google Scholar 

  245. Persichini R, Gay F, Schmidt M, Mayaux J, Demoule A, Morelot-Panzini C, et al. Diagnostic accuracy of respiratory distress observation scales as surrogates of Dyspnea self-report in intensive care unit patients. Anesthesiology. 2015;123(4):830–7.

    Article  PubMed  Google Scholar 

  246. Hechtner M, Eichler M, Wehler B, Buhl R, Sebastian M, Stratmann J, et al. Quality of life in NSCLC survivors - a multicenter cross-sectional study. J Thorac Oncol. 2019;14(3):420–35.

    Article  PubMed  Google Scholar 

  247. Camargo LA, Pereira CA. Dyspnea in COPD: beyond the modified Medical Research Council scale. J Bras Pneumol. 2010;36(5):571–8.

    Article  PubMed  Google Scholar 

  248. Blinderman CD, Homel P, Billings JA, Portenoy RK, Tennstedt SL. Symptom distress and quality of life in patients with advanced congestive heart failure. J Pain Symptom Manag. 2008;35(6):594–603.

    Article  Google Scholar 

  249. Pratter MR, Curley FJ, Dubois J, Irwin RS. Cause and evaluation of chronic dyspnea in a pulmonary disease clinic. Arch Intern Med. 1989;149(10):2277–82.

    Article  CAS  PubMed  Google Scholar 

  250. Pratter MR, Abouzgheib W, Akers S, Kass J, Bartter T. An algorithmic approach to chronic dyspnea. Respir Med. 2011;105(7):1014–21.

    Article  PubMed  Google Scholar 

  251. Meriggi F. Dyspnea in cancer patients: a well-known and neglected symptom. Rev Recent Clin Trials. 2018;13(2):84–8.

    Article  PubMed  Google Scholar 

  252. Renier W, Winckelmann KH, Verbakel JY, Aertgeerts B, Buntinx F. Signs and symptoms in adult patients with acute dyspnea: a systematic review and meta-analysis. Eur J Emerg Med. 2018;25(1):3–11.

    Article  PubMed  Google Scholar 

  253. Hale ZE, Singhal A, Hsia RY. Causes of shortness of breath in the acute patient: a National Study. Acad Emerg Med. 2018;25(11):1227–34.

    Article  PubMed  Google Scholar 

  254. Masago K, Fujita S, Togashi Y, Irisa K, Sakamori Y, Hatachi Y, et al. Association between brain natriuretic peptide and distant metastases in advanced non-small cell lung cancer patients. Oncol Lett. 2011;2(2):253–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  255. Wang XT, Liu DW, Zhang HM, Chai WZ. Integrated cardiopulmonary sonography: a useful tool for assessment of acute pulmonary edema in the intensive care unit. J Ultrasound Med. 2014;33(7):1231–9.

    Article  PubMed  Google Scholar 

  256. Volpicelli G, Silva F, Radeos M. Real-time lung ultrasound for the diagnosis of alveolar consolidation and interstitial syndrome in the emergency department. Eur J Emerg Med. 2010;17(2):63–72.

    Article  PubMed  Google Scholar 

  257. Frassi F, Gargani L, Tesorio P, Raciti M, Mottola G, Picano E. Prognostic value of extravascular lung water assessed with ultrasound lung comets by chest sonography in patients with dyspnea and/or chest pain. J Card Fail. 2007;13(10):830–5.

    Article  PubMed  Google Scholar 

  258. Uhlving HH, Buchvald F, Heilmann CJ, Nielsen KG, Gormsen M, Muller KG. Bronchiolitis obliterans after Allo-SCT: clinical criteria and treatment options. Bone Marrow Transplant. 2012;47(8):1020–9.

    Article  CAS  PubMed  Google Scholar 

  259. Wang X, Liu C, Wang M, Zhang YI, Li H, Liu G. Clinical features of post-infectious bronchiolitis obliterans in children undergoing long-term azithromycin treatment. Exp Ther Med. 2015;9(6):2379–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  260. Ichikawa Y, Ninomiya H, Katsuki M, Hotta M, Tanaka M, Oizumi K. Low-dose/long-term erythromycin for treatment of bronchiolitis obliterans organizing pneumonia (BOOP). Kurume Med J. 1993;40(2):65–7.

    Article  CAS  PubMed  Google Scholar 

  261. Stover DE, Mangino D. Macrolides: a treatment alternative for bronchiolitis obliterans organizing pneumonia? Chest. 2005;128(5):3611–7.

    Article  PubMed  Google Scholar 

  262. Kako J, Kobayashi M, Oosono Y, Kajiwara K, Miyashita M. Immediate effect of fan therapy in terminal cancer with dyspnea at rest: a meta-analysis. Am J Hosp Palliat Care. 2020;37(4):294–9.

    Article  PubMed  Google Scholar 

  263. Ruangsomboon O, Dorongthom T, Chakorn T, Monsomboon A, Praphruetkit N, Limsuwat C, et al. High-flow nasal cannula versus conventional oxygen therapy in relieving dyspnea in emergency palliative patients with do-not-intubate status: a randomized crossover study. Ann Emerg Med. 2019;75:615.

    Article  PubMed  Google Scholar 

  264. Pisani L, Vega ML. Use of nasal high flow in stable COPD: rationale and physiology. COPD. 2017;14(3):346–50.

    Article  PubMed  Google Scholar 

  265. Pisani L, Fasano L, Corcione N, Comellini V, Musti MA, Brandao M, et al. Change in pulmonary mechanics and the effect on breathing pattern of high flow oxygen therapy in stable hypercapnic COPD. Thorax. 2017;72(4):373–5.

    Article  PubMed  Google Scholar 

  266. Nishimura M. High-flow nasal cannula oxygen therapy in adults: physiological benefits, indication, clinical benefits, and adverse effects. Respir Care. 2016;61(4):529–41.

    Article  PubMed  Google Scholar 

  267. Wilson ME, Mittal A, Dobler CC, Curtis JR, Majzoub AM, Soleimani J, et al. High-flow nasal cannula oxygen in patients with acute respiratory failure and do-not-intubate or do-not-resuscitate orders: a systematic review. J Hosp Med. 2020;15(2):101–6.

    Article  PubMed  Google Scholar 

  268. Pisani L, Hill NS, Pacilli AMG, Polastri M, Nava S. Management of dyspnea in the terminally ill. Chest. 2018;154(4):925–34.

    Article  PubMed  Google Scholar 

  269. Vozoris NT. Opioids, chronic obstructive pulmonary disease, and hyperbole. J Palliat Med. 2018;21(6):745.

    Article  PubMed  Google Scholar 

  270. Dy SM GA, Waldfogel JM, Sharma R, Zhang A, Feliciano JL, Sedhom R, Day J, Gersten RA, Davidson PM, Bass EB. Interventions for breathlessness in patients with advanced cancer. Comparative Effectiveness Review No. 232. (Prepared by the Johns Hopkins University Evidence-based Practice Center under Contract No 290–2015-00006-I for the Agency for Healthcare Research and Quality and the Patient-Centered Outcomes Research Institute) AHRQ Publication No 21-EHC024, PCORI Publication No 2020-SR-01. 2020.

    Google Scholar 

  271. Strieder M, Pecherstorfer M, Kreye G. Symptomatic treatment of dyspnea in advanced cancer patients : a narrative review of the current literature. Wien Med Wochenschr. 2018;168(13–14):333–43.

    Article  PubMed  Google Scholar 

  272. Haywood A, Duc J, Good P, Khan S, Rickett K, Vayne-Bossert P, et al. Systemic corticosteroids for the management of cancer-related breathlessness (dyspnoea) in adults. Cochrane Database Syst Rev. 2019;2:CD012704.

    PubMed  Google Scholar 

  273. Hui D, Kilgore K, Frisbee-Hume S, Park M, Tsao A, Delgado Guay M, et al. Dexamethasone for dyspnea in cancer patients: a pilot double-blind, randomized, controlled trial. J Pain Symptom Manag. 2016;52(1):8–16 e1.

    Article  Google Scholar 

  274. Dogan N, Tasci S. The effects of acupressure on quality of life and dyspnea in lung cancer: a randomized, controlled trial. Altern Ther Health Med. 2020;26(1):49–56.

    PubMed  Google Scholar 

  275. Hernandez A, Bronas UG, Steffen AD, Marquez DX, Fritschi C, Quinn LT, et al. Rhythmic auditory stimulation increases 6-minute walk distance in individuals with COPD: a repeated measures study. Heart Lung. 2020;49:324.

    Article  PubMed  Google Scholar 

  276. Ratarasarn K, Kundu A. Yoga and tai chi: a mind-body approach in managing respiratory symptoms in obstructive lung diseases. Curr Opin Pulm Med. 2020;26(2):186–92.

    Article  PubMed  Google Scholar 

  277. Kanezaki M, Ebihara S. Effect of the cooling sensation induced by olfactory stimulation by L-menthol on dyspnoea: a pilot study. Eur Respir J. 2017;49(4):1601823.

    Article  PubMed  Google Scholar 

  278. Jackson P, Khan A. Delirium in critically ill patients. Crit Care Clin. 2015;31(3):589–603.

    Article  PubMed  Google Scholar 

  279. Siddiqi N, House AO, Holmes JD. Occurrence and outcome of delirium in medical in-patients: a systematic literature review. Age Ageing. 2006;35(4):350–64.

    Article  PubMed  Google Scholar 

  280. Maldonado JR. Acute brain failure: pathophysiology, diagnosis, management, and sequelae of delirium. Crit Care Clin. 2017;33(3):461–519.

    Article  PubMed  Google Scholar 

  281. Morandi A, Bellelli G. Delirium superimposed on dementia. Eur Geriatr Med. 2020;11(1):53–62.

    Article  PubMed  Google Scholar 

  282. Ljubisavljevic V, Kelly B. Risk factors for development of delirium among oncology patients. Gen Hosp Psychiatry. 2003;25(5):345–52.

    Article  PubMed  Google Scholar 

  283. Fann JR, Roth-Roemer S, Burington BE, Katon WJ, Syrjala KL. Delirium in patients undergoing hematopoietic stem cell transplantation. Cancer. 2002;95(9):1971–81.

    Article  PubMed  Google Scholar 

  284. Lawlor PG, Bush SH. Delirium diagnosis, screening and management. Curr Opin Support Palliat Care. 2014;8(3):286–95.

    Article  PubMed  PubMed Central  Google Scholar 

  285. Leonard MM, Nekolaichuk C, Meagher DJ, Barnes C, Gaudreau JD, Watanabe S, et al. Practical assessment of delirium in palliative care. J Pain Symptom Manag. 2014;48(2):176–90.

    Article  Google Scholar 

  286. Inouye SK, Foreman MD, Mion LC, Katz KH, Cooney LM Jr. Nurses' recognition of delirium and its symptoms: comparison of nurse and researcher ratings. Arch Intern Med. 2001;161(20):2467–73.

    Article  CAS  PubMed  Google Scholar 

  287. Maldonado JR. Delirium pathophysiology: an updated hypothesis of the etiology of acute brain failure. Int J Geriatr Psychiatry. 2018;33(11):1428–57.

    Article  PubMed  Google Scholar 

  288. Thom R, Silbersweig DA, Boland RJ. Major depressive disorder in medical illness: a review of assessment, prevalence, and treatment options. Psychosom Med. 2019;81(3):246–55.

    Article  PubMed  Google Scholar 

  289. Oldham MA, Flanagan NM, Khan A, Boukrina O, Marcantonio ER. Responding to ten common delirium misconceptions with best evidence: an educational review for clinicians. J Neuropsychiatr Clin Neurosci. 2018;30(1):51–7.

    Article  Google Scholar 

  290. Choi SH, Lee H, Chung TS, Park KM, Jung YC, Kim SI, et al. Neural network functional connectivity during and after an episode of delirium. Am J Psychiatry. 2012;169(5):498–507.

    Article  PubMed  Google Scholar 

  291. Jones RN, Cizginer S, Pavlech L, Albuquerque A, Daiello LA, Dharmarajan K, et al. Assessment of instruments for measurement of delirium severity: a systematic review. JAMA Intern Med. 2019;179(2):231–9.

    Article  PubMed  PubMed Central  Google Scholar 

  292. MacLullich AM, Shenkin SD, Goodacre S, Godfrey M, Hanley J, Stiobhairt A, et al. The 4 'A's test for detecting delirium in acute medical patients: a diagnostic accuracy study. Health Technol Assess. 2019;23(40):1–194.

    Article  PubMed  PubMed Central  Google Scholar 

  293. Shenkin SD, Fox C, Godfrey M, Siddiqi N, Goodacre S, Young J, et al. Delirium detection in older acute medical inpatients: a multicentre prospective comparative diagnostic test accuracy study of the 4AT and the confusion assessment method. BMC Med. 2019;17(1):138.

    Article  PubMed  PubMed Central  Google Scholar 

  294. Numan T, van den Boogaard M, Kamper AM, Rood PJT, Peelen LM, Slooter AJC, et al. Delirium detection using relative delta power based on 1-minute single-channel EEG: a multicentre study. Br J Anaesth. 2019;122(1):60–8.

    Article  CAS  PubMed  Google Scholar 

  295. Inouye SK, Bogardus ST Jr, Charpentier PA, Leo-Summers L, Acampora D, Holford TR, et al. A multicomponent intervention to prevent delirium in hospitalized older patients. N Engl J Med. 1999;340(9):669–76.

    Article  CAS  PubMed  Google Scholar 

  296. Hosie A, Phillips J, Lam L, Kochovska S, Noble B, Brassil M, et al. Multicomponent non-pharmacological intervention to prevent delirium for hospitalised people with advanced cancer: study protocol for a phase II cluster randomised controlled trial. BMJ Open. 2019;9(1):e026177.

    Article  PubMed  PubMed Central  Google Scholar 

  297. Bush SH, Bruera E, Lawlor PG, Kanji S, Davis DH, Agar M, et al. Clinical practice guidelines for delirium management: potential application in palliative care. J Pain Symptom Manag. 2014;48(2):249–58.

    Article  Google Scholar 

  298. Gaertner J, Eychmueller S, Leyhe T, Bueche D, Savaskan E, Schlogl M. Benzodiazepines and/or neuroleptics for the treatment of delirium in palliative care?-a critical appraisal of recent randomized controlled trials. Ann Palliat Med. 2019;8(4):504–15.

    Article  PubMed  Google Scholar 

  299. Shrikant KN. No reduction in delirium with the use of haloperidol or ziprasidone in critically ill patients. Am Fam Physician. 2019;99(7):460–1.

    Google Scholar 

  300. Riviere J, van der Mast RC, Vandenberghe J, Van Den Eede F. Efficacy and tolerability of atypical antipsychotics in the treatment of delirium: a systematic review of the literature. Psychosomatics. 2019;60(1):18–26.

    Article  PubMed  Google Scholar 

  301. Nikooie R, Neufeld KJ, Oh ES, Wilson LM, Zhang A, Robinson KA, et al. Antipsychotics for treating delirium in hospitalized adults: a systematic review. Ann Intern Med. 2019;171:485.

    Article  PubMed  Google Scholar 

  302. van der Vorst M, Neefjes ECW, Boddaert MSA, Verdegaal B, Beeker A, Teunissen SCC, et al. Olanzapine versus haloperidol for treatment of delirium in patients with advanced cancer: a phase III randomized clinical trial. Oncologist. 2019;25:e570.

    Article  PubMed  PubMed Central  Google Scholar 

  303. Tenser RB. Haloperidol and ziprasidone for treatment of delirium in critical illness. N Engl J Med. 2019;380(18):1778.

    Article  PubMed  Google Scholar 

  304. Shen YZ, Peng K, Zhang J, Meng XW, Ji FH. Effects of haloperidol on delirium in adult patients: a systematic review and meta-analysis. Med Princ Pract. 2018;27(3):250–9.

    Article  PubMed  PubMed Central  Google Scholar 

  305. Vondeling AM, Knol W, Egberts TCG, Slooter AJC. Anticholinergic drug exposure at intensive care unit admission affects the occurrence of delirium. A prospective cohort study. Eur J Intern Med. 2020;78:121–6.

    Article  CAS  PubMed  Google Scholar 

  306. Lawley H, Hewison A. An integrative literature review exploring the clinical management of delirium in patients with advanced cancer. J Clin Nurs. 2017;26(23–24):4172–83.

    Article  PubMed  Google Scholar 

  307. Sun R, Wang S, Li S, Yang C, Zhao Y, Luo A. Effects of dexmedetomidine on delirium and mortality during sedation in ICU patients: a systematic review and meta-analysis protocol. BMJ Open. 2019;9(4):e025850.

    Article  PubMed  PubMed Central  Google Scholar 

  308. Maagaard M, Barbateskovic M, Perner A, Jakobsen JC, Wetterslev J. Dexmedetomidine for the management of delirium in critically ill patients-a protocol for a systematic review. Acta Anaesthesiol Scand. 2019;63(4):549–57.

    Article  PubMed  Google Scholar 

  309. Marra A, McGrane TJ, Henson CP, Pandharipande PP. Melatonin in critical care. Crit Care Clin. 2019;35(2):329–40.

    Article  PubMed  Google Scholar 

  310. Foster J, Burry LD, Thabane L, Choong K, Menon K, Duffett M, et al. Melatonin and melatonin agonists to prevent and treat delirium in critical illness: a systematic review protocol. Syst Rev. 2016;5(1):199.

    Article  PubMed  PubMed Central  Google Scholar 

  311. Alagiakrishnan K. Melatonin based therapies for delirium and dementia. Discov Med. 2016;21(117):363–71.

    PubMed  Google Scholar 

  312. Baumgartner L, Lam K, Lai J, Barnett M, Thompson A, Gross K, et al. Effectiveness of melatonin for the prevention of intensive care unit delirium. Pharmacotherapy. 2019;39(3):280–7.

    Article  CAS  PubMed  Google Scholar 

  313. Hatta K, Kishi Y, Wada K, Takeuchi T, Odawara T, Usui C, et al. Preventive effects of ramelteon on delirium: a randomized placebo-controlled trial. JAMA Psychiatry. 2014;71(4):397–403.

    Article  CAS  PubMed  Google Scholar 

  314. Sanford AM, Flaherty JH. Do nutrients play a role in delirium? Curr Opin Clin Nutr Metab Care. 2014;17(1):45–50.

    CAS  PubMed  Google Scholar 

  315. Guo Y, Li Y, Zhang Y, Fang S, Xu X, Zhao A, et al. Post-operative delirium associated with metabolic alterations following hemi-arthroplasty in older patients. Age Ageing. 2019;49(1):88–95.

    Article  PubMed  Google Scholar 

  316. Crowley KE, Urben L, Hacobian G, Geiger KL. Valproic acid for the management of agitation and delirium in the intensive care setting: a retrospective analysis. Clin Ther. 2020;42:e65.

    Article  CAS  PubMed  Google Scholar 

  317. Yeo QM, Wiley TL, Smith MN, Hammond DA. Oral agents for the management of agitation and agitated delirium in critically ill patients. Crit Care Nurs Q. 2017;40(4):344–62.

    Article  PubMed  Google Scholar 

  318. Gagnon DJ, Fontaine GV, Riker RR, Fraser GL. Repurposing valproate, enteral clonidine, and phenobarbital for comfort in adult ICU patients: a literature review with practical considerations. Pharmacotherapy. 2017;37(10):1309–21.

    Article  PubMed  Google Scholar 

  319. Gagnon DJ, Fontaine GV, Smith KE, Riker RR, Miller RR 3rd, Lerwick PA, et al. Valproate for agitation in critically ill patients: a retrospective study. J Crit Care. 2017;37:119–25.

    Article  CAS  PubMed  Google Scholar 

  320. Sher Y, Miller Cramer AC, Ament A, Lolak S, Maldonado JR. Valproic acid for treatment of hyperactive or mixed delirium: rationale and literature review. Psychosomatics. 2015;56(6):615–25.

    Article  PubMed  Google Scholar 

  321. Asadollahi S, Heidari K, Hatamabadi H, Vafaee R, Yunesian S, Azadbakht A, et al. Efficacy and safety of valproic acid versus haloperidol in patients with acute agitation: results of a randomized, double-blind, parallel-group trial. Int Clin Psychopharmacol. 2015;30(3):142–50.

    Article  PubMed  Google Scholar 

  322. Potharajaroen S, Tangwongchai S, Tayjasanant T, Thawitsri T, Anderson G, Maes M. Bright light and oxygen therapies decrease delirium risk in critically ill surgical patients by targeting sleep and acid-base disturbances. Psychiatry Res. 2018;261:21–7.

    Article  PubMed  Google Scholar 

  323. Estrup S, Kjer CKW, Poulsen LM, Gogenur I, Mathiesen O. Delirium and effect of circadian light in the intensive care unit: a retrospective cohort study. Acta Anaesthesiol Scand. 2018;62(3):367–75.

    Article  CAS  PubMed  Google Scholar 

  324. Krebber AM, Buffart LM, Kleijn G, Riepma IC, de Bree R, Leemans CR, et al. Prevalence of depression in cancer patients: a meta-analysis of diagnostic interviews and self-report instruments. Psycho-Oncology. 2014;23(2):121–30.

    Article  CAS  PubMed  Google Scholar 

  325. Block SD. Psychological issues in end-of-life care. J Palliat Med. 2006;9(3):751–72.

    Article  PubMed  Google Scholar 

  326. Trivedi MH, Wisniewski SR, Morris DW, Fava M, Gollan JK, Warden D, et al. Concise health risk tracking scale: a brief self-report and clinician rating of suicidal risk. J Clin Psychiatry. 2011;72(6):757–64.

    Article  PubMed  Google Scholar 

  327. Amonoo HL, Fenech A, Greer JA, Temel JS, Huffman JC, El-Jawahri A. Does desire to pursue pleasurable activities matter? The impact of pretransplantation anhedonia on quality of life and fatigue in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2020;26(8):1477–81.

    Article  PubMed  Google Scholar 

  328. Fujisawa D. Depression in cancer care. Keio J Med. 2018;67(3):37–44.

    Article  PubMed  Google Scholar 

  329. Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, Churchill R, et al. Mirtazapine versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2011;12:CD006528.

    Google Scholar 

  330. Barbosa MG, Delfino RS, Sarin LM, Jackowski AP. Repeated subcutaneous esketamine administration for depressive symptoms and pain relief in a terminally ill cancer patient: a case report. Palliat Med. 2020;34(6):822–5.

    Article  PubMed  Google Scholar 

  331. Falk E, Schlieper D, van Caster P, Lutterbeck MJ, Schwartz J, Cordes J, et al. A rapid positive influence of S-ketamine on the anxiety of patients in palliative care: a retrospective pilot study. BMC Palliat Care. 2020;19(1):1.

    Article  PubMed  PubMed Central  Google Scholar 

  332. Tremblay A, Breitbart W. Psychiatric dimensions of palliative care. Neurol Clin. 2001;19(4):949–67.

    Article  CAS  PubMed  Google Scholar 

  333. Lloyd-Williams M, Friedman T, Rudd N. An analysis of the validity of the hospital anxiety and depression scale as a screening tool in patients with advanced metastatic cancer. J Pain Symptom Manag. 2001;22(6):990–6.

    Article  CAS  Google Scholar 

  334. Reuben DB, Mor V. Nausea and vomiting in terminal cancer patients. Arch Intern Med. 1986;146(10):2021–3.

    Article  CAS  PubMed  Google Scholar 

  335. Morran C, Smith DC, Anderson DA, McArdle CS. Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomised trial of antiemetics. Br Med J. 1979;1(6174):1323–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  336. Gao S, Zhang M, Wu K, Zhu J, He Z, Li J, et al. Risk of adverse events in lymphoma patients treated with brentuximab vedotin: a systematic review and meta-analysis. Expert Opin Drug Saf. 2020;19(5):617–23.

    Article  CAS  PubMed  Google Scholar 

  337. Di Renzo N, Musso M, Scime R, Cupri A, Perrone T, De Risi C, et al. Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple-day and high-dose chemotherapy in patients with non-Hodgkin's lymphoma undergoing autologous hematopoietic stem cell transplantation: a phase IIa, multicenter study. Bone Marrow Transplant. 2020;55:2114.

    Article  PubMed  PubMed Central  Google Scholar 

  338. Tendas A, Marchesi F, Mengarelli A, Annibali O, Tomarchio V, Saltarelli D, et al. Prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan and stem cell transplantation: review of the evidence and suggestions. Support Care Cancer. 2019;27(3):793–803.

    Article  PubMed  Google Scholar 

  339. Crossnohere NL, Richardson DR, Reinhart C, O'Donoghue B, Love SM, Smith BD, et al. Side effects from acute myeloid leukemia treatment: results from a national survey. Curr Med Res Opin. 2019;35(11):1965–70.

    Article  PubMed  Google Scholar 

  340. Rizio AA, White MK, McCausland KL, Quock TP, Guthrie SD, Yokota M, et al. Treatment tolerability in patients with immunoglobulin light-chain amyloidosis. Am Health Drug Benefits. 2018;11(8):430–7.

    PubMed  PubMed Central  Google Scholar 

  341. Kuchuk I, Bouganim N, Beusterien K, Grinspan J, Vandermeer L, Gertler S, et al. Preference weights for chemotherapy side effects from the perspective of women with breast cancer. Breast Cancer Res Treat. 2013;142(1):101–7.

    Article  CAS  PubMed  Google Scholar 

  342. Roscoe JA, Morrow GR, Aapro MS, Molassiotis A, Olver I. Anticipatory nausea and vomiting. Support Care Cancer. 2011;19(10):1533–8.

    Article  PubMed  Google Scholar 

  343. Morrow GR. Susceptibility to motion sickness and the development of anticipatory nausea and vomiting in cancer patients undergoing chemotherapy. Cancer Treat Rep. 1984;68(9):1177–8.

    CAS  PubMed  Google Scholar 

  344. Stephenson J, Davies A. An assessment of aetiology-based guidelines for the management of nausea and vomiting in patients with advanced cancer. Support Care Cancer. 2006;14(4):348–53.

    Article  PubMed  Google Scholar 

  345. Hui D, Bruera E. The Edmonton symptom assessment system 25 years later: past, present, and future developments. J Pain Symptom Manag. 2017;53(3):630–43.

    Article  Google Scholar 

  346. Cheng AW, Abdeljaber M, Lima NA, Shebrain S. Large bowel obstruction in the setting of small lymphocytic lymphoma. Cureus. 2020;12(8):e9640.

    PubMed  PubMed Central  Google Scholar 

  347. Kasparian S, Burns E, Shehabeldin A, Awar M, Pingali SR. Recurrent small bowel obstruction caused by Burkitt lymphoma in an elderly man: a case report and review of the literature. J Med Case Rep. 2020;14(1):127.

    Article  PubMed  PubMed Central  Google Scholar 

  348. Shirwaikar Thomas A, Schwartz M, Quigley E. Gastrointestinal lymphoma: the new mimic. BMJ Open Gastroenterol. 2019;6(1):e000320.

    Article  PubMed  PubMed Central  Google Scholar 

  349. Menke DM, Kyle RA, Fleming CR, Wolfe JT 3rd, Kurtin PJ, Oldenburg WA. Symptomatic gastric amyloidosis in patients with primary systemic amyloidosis. Mayo Clin Proc. 1993;68(8):763–7.

    Article  CAS  PubMed  Google Scholar 

  350. Coluzzi F, Rolke R, Mercadante S. Pain management in patients with multiple myeloma: an update. Cancers (Basel). 2019;11(12):2037.

    Article  CAS  PubMed  Google Scholar 

  351. Sloot S, Boland J, Snowden JA, Ezaydi Y, Foster A, Gethin A, et al. Side effects of analgesia may significantly reduce quality of life in symptomatic multiple myeloma: a cross-sectional prevalence study. Support Care Cancer. 2015;23(3):671–8.

    Article  PubMed  Google Scholar 

  352. Glare P, Walsh D, Sheehan D. The adverse effects of morphine: a prospective survey of common symptoms during repeated dosing for chronic cancer pain. Am J Hosp Palliat Care. 2006;23(3):229–35.

    Article  PubMed  Google Scholar 

  353. Cherny N, Ripamonti C, Pereira J, Davis C, Fallon M, McQuay H, et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol. 2001;19(9):2542–54.

    Article  CAS  PubMed  Google Scholar 

  354. Razvi Y, Chan S, McFarlane T, McKenzie E, Zaki P, DeAngelis C, et al. ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients. Support Care Cancer. 2019;27(1):87–95.

    Article  PubMed  Google Scholar 

  355. Grunberg SM, Osoba D, Hesketh PJ, Gralla RJ, Borjeson S, Rapoport BL, et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--an update. Support Care Cancer. 2005;13(2):80–4.

    Article  PubMed  Google Scholar 

  356. Jordan K, Chan A, Gralla RJ, Jahn F, Rapoport B, Warr D, et al. 2016 updated MASCC/ESMO consensus recommendations: emetic risk classification and evaluation of the emetogenicity of antineoplastic agents. Support Care Cancer. 2017;25(1):271–5.

    Article  PubMed  Google Scholar 

  357. Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer. 2004;100(10):2261–8.

    Article  PubMed  Google Scholar 

  358. Aapro M, Zhang L, Yennu S, LeBlanc TW, Schwartzberg L. Preventing chemotherapy-induced nausea and vomiting with netupitant/palonosetron, the first fixed combination antiemetic: current and future perspective. Future Oncol. 2019;15(10):1067–84.

    Article  CAS  PubMed  Google Scholar 

  359. Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;375(2):134–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  360. Berger MJ, Ettinger DS, Aston J, Barbour S, Bergsbaken J, Bierman PJ, et al. NCCN guidelines insights: antiemesis, Version 2.2017. J Natl Compr Cancer Netw. 2017;15(7):883–93.

    Article  Google Scholar 

  361. Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, et al. Antiemetics: ASCO guideline update. J Clin Oncol. 2020;38:JCO2001296.

    Article  Google Scholar 

  362. Herrstedt J, Roila F, Warr D, Celio L, Navari RM, Hesketh PJ, et al. 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high emetic risk chemotherapy. Support Care Cancer. 2017;25(1):277–88.

    Article  PubMed  Google Scholar 

  363. Einhorn LH, Rapoport B, Navari RM, Herrstedt J, Brames MJ. 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer. 2017;25(1):303–8.

    Article  PubMed  Google Scholar 

  364. Hardy J, Skerman H, Glare P, Philip J, Hudson P, Mitchell G, et al. A randomized open-label study of guideline-driven antiemetic therapy versus single agent antiemetic therapy in patients with advanced cancer and nausea not related to anticancer treatment. BMC Cancer. 2018;18(1):510.

    Article  PubMed  PubMed Central  Google Scholar 

  365. Davis MP, Hallerberg G. Palliative medicine study group of the multinational association of supportive care in c. a systematic review of the treatment of nausea and/or vomiting in cancer unrelated to chemotherapy or radiation. J Pain Symptom Manag. 2010;39(4):756–67.

    Article  Google Scholar 

  366. Navari RM, Pywell CM, Le-Rademacher JG, White P, Dodge AB, Albany C, et al. Olanzapine for the treatment of advanced cancer-related chronic nausea and/or vomiting: a randomized pilot trial. JAMA Oncol. 2020;6(6):895–9.

    Article  PubMed  Google Scholar 

  367. Davis MP. Cannabinoids for symptom management and cancer therapy: the evidence. J Natl Compr Cancer Netw. 2016;14(7):915–22.

    Article  CAS  Google Scholar 

  368. Winston AW, Rinehart RS, Riley GP, Vacchiano CA, Pellegrini JE. Comparison of inhaled isopropyl alcohol and intravenous ondansetron for treatment of postoperative nausea. AANA J. 2003;71(2):127–32.

    PubMed  Google Scholar 

  369. Verma DK, Bansal S, Sharma P, Sundararaman P. Control of postoperative nausea and vomiting in oral and maxillofacial surgery patients with isopropyl alcohol: a prospective randomized clinical trial. J Maxillofac Oral Surg. 2018;17(4):576–81.

    Article  PubMed  PubMed Central  Google Scholar 

  370. Teran L, Hawkins JK. The effectiveness of inhalation isopropyl alcohol vs. granisetron for the prevention of postoperative nausea and vomiting. AANA J. 2007;75(6):417–22.

    PubMed  Google Scholar 

  371. Schwartz A. Comparison of inhalation of isopropyl alcohol vs promethazine in the treatment of postoperative nausea and vomiting (PONV) in patients identified as high risk for developing PONV. AANA J. 2009;77(6):417–8. author reply 8

    PubMed  Google Scholar 

  372. Radford KD, Fuller TN, Bushey B, Daniel C, Pellegrini JE. Prophylactic isopropyl alcohol inhalation and intravenous ondansetron versus ondansetron alone in the prevention of postoperative nausea and vomiting in high-risk patients. AANA J. 2011;79(4 Suppl):S69–74.

    PubMed  Google Scholar 

  373. Pellegrini J, DeLoge J, Bennett J, Kelly J. Comparison of inhalation of isopropyl alcohol vs promethazine in the treatment of postoperative nausea and vomiting (PONV) in patients identified as at high risk for developing PONV. AANA J. 2009;77(4):293–9.

    PubMed  Google Scholar 

  374. Beadle KL, Helbling AR, Love SL, April MD, Hunter CJ. Isopropyl alcohol nasal inhalation for nausea in the emergency department: a randomized controlled trial. Ann Emerg Med. 2016;68(1):1–9 e1.

    Article  PubMed  Google Scholar 

  375. Dupuis LL, Roscoe JA, Olver I, Aapro M, Molassiotis A. 2016 updated MASCC/ESMO consensus recommendations: anticipatory nausea and vomiting in children and adults receiving chemotherapy. Support Care Cancer. 2017;25(1):317–21.

    Article  PubMed  Google Scholar 

  376. Zeltzer LK, Dolgin MJ, LeBaron S, LeBaron C. A randomized, controlled study of behavioral intervention for chemotherapy distress in children with cancer. Pediatrics. 1991;88(1):34–42.

    CAS  PubMed  Google Scholar 

  377. Varejao CDS, Santo F. Laser acupuncture for relieving nausea and vomiting in pediatric patients undergoing chemotherapy: a single-blind randomized clinical trial. J Pediatr Oncol Nurs. 2019;36(1):44–54.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mellar Davis .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2023 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Davis, M., Fernandez, C., Vithalani, N., Nicholls, L.E., Digwood, G. (2023). Symptoms in Advanced Hematologic Malignancies and Other Serious Hematologic Conditions. In: Ullrich, C.K., Roeland, E.J. (eds) Palliative Care in Hematologic Malignancies and Serious Blood Disorders. Springer, Cham. https://doi.org/10.1007/978-3-031-38058-7_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-38058-7_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-38057-0

  • Online ISBN: 978-3-031-38058-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics